There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost. Early genetic assessment of expression cell lines can support cell line characterisation and can help to confirm identify stability concerns at an early stage. Join us to learn more.